IMMUNOLOGICAL PROFILE OF ACUTE MYELOID LEUKEMIA IN KURDISTAN IRAQ

SANA DLAWAR JALAL

SANA DLAWAR JALAL Department of Pathology, College of Medicine, University of Sulaimani, Kurdistan Region, Iraq.

Keywords: Acute myeloid leukemia, Immunophenotyping, Flow cytometry, FrenchAmerican- British

Abstract

https://doi.org/10.31386/dmj.uod.18.12.1.1

Background: Immunophenotyping has become crucial in the diagnosis and classification of acute leukemias and identification of its aberrant phenotypes. This study aimed to evaluate the patterns in AML cases presented to the flowcytometry unit at the Sulaimani Public Health Laboratory, Kurdistan, Iraq,and to determine the frequency of aberrant expression of lymphoid associated antigen. Subject and Methods: For the above purposes, 108 cases of acute myeloid leukemia (AML) were evaluated morphologically,and by flowcytometry with a panel of 22 antibodies. Furthermore, any aberrant expression of lymphoid associated antigens was reported. Results: The morphological AML subtyping revealed that 29.6% of AML cases were M2, while M1 (36.1%) was the predominant subtype by immunophenotyping using WHO 2008 classification. CD117, CD45, CD13 and CD33 were the most frequently expressed markers (99.1%, 92.6%, 92.6% and 85.2% respectively). Forty-five patients (41.7%) expressed lymphoid associated antigens (nTdT, CD19, CD79a, CD10, CD4, CD56 and CD9) that was demonstrated in all AML subtypesexcept M6.CD56 was the most frequent(13%),followed by CD9 (12%), CD4 (8.3%), and CD19 (7.4%).CD79a, nTdT and CD10 were less frequent, present in <5% of cases each. Conclusions: Immunophenotyping is an essential supplement to morphology in AML, whether for confirmation or accurate subtyping. Furthermore, more than 40% of cases show aberrant lymphoid antigen expression. The latter may serve as an important tool in future studies on minimal residual disease evaluation.

Downloads

Download data is not yet available.

References

1. Walter K, Cockerill PN, Barlow R, Clarke D, Hoogenkamp M, Follows GA, e t al. Aberrant expression of CD19 in AML with t (8; 21) involves a poised chromatin structure and PAX5. Oncogene. 2010; 29(20): 2927-2937.
2. De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood cancer J. 2016; 6(7): e441.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. The 2008 WHO classification of lymphoid neoplasim and beyond evolving concepts and practical applications. Blood. 2011; 117(19): 5019–5032.
4. Chang F, Shamsi TS, Waryah AM, "Clinical and Hematological Profile of Acute Myeloid Leukemia (AML) Patients of Sindh. J Hematol Thrombo Dis. 2016; 4 (2) 4:239.
5. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloidleukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood .2010; 115(3): 453-474.
6. Ossenkoppele GJ, van de Loosdrecht AA, Schuurhuis GJ. Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms. Br J Haematol .2011; 153(4): 421-436.
7. Peters JM, Ansari MQ. Multiparameter flow cytometry in the diagnosis and management of acute leukemia. Arch Pathol Lab Med 2011; 135(1): 44-54.
8. Shorbagy S, Haggag R, Alazizi N, Abouzeid T. CD56 and CD19 Antigens Expression in Acute Myeloid Leukemia Identifies Patients with Adverse Prognosis in Egypt. Int J Science Res. 2016; 5 (1): 2319-7064.
9. Pouls RK, Shamoon RP, Muhammed NS. Clinical and haematological parameters in adult AML patients: a four year experience at Nanakaly Hospital for blood diseases. Zanco J Med Sci .2012; 16 (3): 199-203.
10. Al Allawi NAS, Hilmi FA, Yahya HI, Wajdi FT, Al Saleem TI, Al-Kassab F. Acute myeloid leukaemia: Morphological subtyping and hasematological findings in 214 Iraqi Adults. J Fac Med Bagdad. 1991; 33 (1):59-71.
11. Al-Anizi WM, Al-Mashta MA. The frequency of aberrant lymphoid antigens expression in 202 Iraqi patients with de novo
acute myeloid leukemia. Iraqi J Helmatol .2017; 6(2): 49-54.
12. Osman IM, Humeida AA, Eltayeb O, Abdulrahman I, Elhadi TA. Flowcytometric Immunophenotypic characterization of acute myeloid leukemia (AML) in Sudan. Int J Hematol Dis. 2015; 2(1): 10-17.
13. Salem DA, Abd El-Aziz SM. Flowcytometric immunophenotypic profile of acute leukemia: Mansoura experience. Indian J Hematol blood transfus. 2012; 28(2): 89-96.
14. Ghosh S, Shinde SC, Kumaran GS, Sapre RS, Dhond SR, Badrinath Y, et al. Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital. Indian J Cancer. 2003; 40(2): 71-6.
15. Kaleem Z, Crawford E, Pathan MH, Jasper L, Covinsky MA, Johnson LR, et al. Flow cytometric analysis of acute leukemias: diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003; 127(1): 42-48.
16. Bain BJ. Immunophenotyping and Cytogenetic/Molecular Genetic Analysis in Leukaemia and Related Conditions .Leukaemia Diagnosis, Fourth Edition, Wiley-Blackwell. Oxford. UK;2010
17. Khalidi HS, Medeiros LJ, Chang KL, Brynes RK, Slovak ML, Arber DA. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities. Am J Clinic Pathol .1998; 109(2): 211-220.
18. Bahia DM, Yamamoto M, Mde LC, Kimura EY, Bordin JO, Filgueiras MA ,et al .Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica. 2001; 86(8): 801-806.
19. Jha R, Grover G, Bose P. Lymphoid associated antigen expression in new cases of Acute Myeloid Leukemia. J Pathol Nepal. 2013; 3(6): 487-490.
20. El-Sissy AH, El-Mashari MA, Bassuni WY, El-Swaayed AF. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Canc Inst. 2006; 18(3): 244-9.